Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (clinicaltrials.gov) - Sep 2, 2026 - P2 | N=8 | Active, not recruiting | Sponsor: Stanford University | Recruiting ➔ Active, not recruiting
Enrollment closed • Chronic Eosinophilic Leukemia • Eosinophilia • Hematological Disorders • Hematological Malignancies • Hepatology • Hypereosinophilic Syndrome • Immunology • Leukemia • Oncology • ETV6 • JAK2 • PCM1
|